Last reviewed · How we verify
Levetiracetam/Clonazepam
This combination drug pairs levetiracetam, which modulates synaptic vesicle proteins to reduce neuronal excitability, with clonazepam, a benzodiazepine that enhances GABAergic inhibition in the central nervous system.
This combination drug pairs levetiracetam, which modulates synaptic vesicle proteins to reduce neuronal excitability, with clonazepam, a benzodiazepine that enhances GABAergic inhibition in the central nervous system. Used for Seizure disorders / Epilepsy (combination therapy), Status epilepticus (acute seizure management).
At a glance
| Generic name | Levetiracetam/Clonazepam |
|---|---|
| Also known as | Association of two anti-epileptic drugs in first line |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Anticonvulsant combination (SV2A modulator + benzodiazepine) |
| Target | SV2A (synaptic vesicle protein 2A) and GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Levetiracetam binds to synaptic vesicle protein 2A (SV2A) and reduces calcium influx at presynaptic terminals, thereby decreasing neurotransmitter release and neuronal hyperexcitability. Clonazepam potentiates GABA-A receptor signaling, increasing chloride influx and hyperpolarizing neurons. Together, they provide dual anticonvulsant mechanisms targeting both synaptic modulation and GABAergic inhibition.
Approved indications
- Seizure disorders / Epilepsy (combination therapy)
- Status epilepticus (acute seizure management)
Common side effects
- Somnolence / Sedation
- Dizziness
- Ataxia / Coordination impairment
- Cognitive impairment
- Dependence / Withdrawal risk (clonazepam component)
Key clinical trials
- Study of Antiepileptic Drug in Generalised Convulsive Status Epilepticus (PHASE3)
- Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
- Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy (NA)
- Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
- Ketogenic Diet in Infants With Epilepsy (KIWE) (PHASE4)
- Ketogenic Diet vs.Antiepileptic Drug Treatment in Drug Resistant Epilepsy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levetiracetam/Clonazepam CI brief — competitive landscape report
- Levetiracetam/Clonazepam updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI